-

Cosette Pharmaceuticals Acquires Ambien® and Ambien CR® (Zolpidem Tartrate) Tabs from Sanofi US in the US Market

Seamless Transition Ensures Continued Supply for Patients Who Depend on Ambien®

Acquisition Builds on Cosette’s Leading Expertise in Carving Out Critical Drugs from Global Pharma Companies

original Ambien (Photo: Business Wire)

Ambien (Photo: Business Wire)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company, has completed the acquisition of Ambien® and Ambien CR® in the United States from Sanofi US.

“We are excited at the addition of Ambien to our portfolio,” stated Apurva Saraf, President and CEO of Cosette. “We continue to leverage our demonstrated, best-in-class capabilities in executing complex carve-outs and integrating diverse products. This acquisition not only strengthens our product portfolio but also reaffirms our commitment to ensuring high-quality products continue to remain available to patients worldwide."

According to IQVIA®, U.S. annual sales for Ambien® and Ambien® CR for the 12 months ended April 2024 were $39 million.

Cosette has a history of successfully acquiring or carving-out and integrating products from companies across Japan, Europe, and the USA. Our strategic approach and deep industry expertise help us make divestiture and product transition seamless, ensuring uninterrupted access to critical medicines for millions of patients.

Patients and providers can learn more about Ambien® and Ambien CR®, including Important Safety Information, at www.ambien.com

About Cosette Pharmaceuticals:

Cosette Pharmaceuticals, Inc. (“Cosette”) is a US-based, fully integrated pharmaceutical company with a fast-growing portfolio of branded pharmaceuticals consisting of products in women’s health, cardiology and dermatology. Cosette has a long history in quality manufacturing of complex dosage forms including topical creams, ointments, oral liquids/solutions and suppositories. Cosette has corporate and manufacturing facilities in New Jersey and North Carolina and is supported by 300+ dedicated employees across all functional areas. Cosette is backed by Avista Capital Partners, a healthcare focused private equity firm.

Visit www.cosettepharma.com and follow us on LinkedIn.

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

Industry:

Cosette Pharmaceuticals, Inc.

Details
Headquarters: Bridgewater, New Jersey, USA
CEO: Apurva Saraf
Employees: 350
Organization: PRI
Release Versions
English
Hashtags
#ambien
#cosettepharma
#growth
#health
#healthcare
#pharmaceuticalindustry
#pharmaceuticalmanufacturing
#pharmaceuticals
#privateequity

Contacts

Business Development: bd@cosettepharma.com
Commercial: sales@cosettepharma.com

Social Media Profiles
Cosette Pharmaceuticals, Inc.
More News From Cosette Pharmaceuticals, Inc.

Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days Competitive Generic Therapy (CGT) exclusivity

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved Cosette’s Abbreviated New Drug Application (ANDA) for the first generic version of CIPRO® HC (ciprofloxacin 0.2% HCl and hydrocortisone 1% otic suspension), with 180 days of Competitive Generic Therapy (CGT) exclusivity. Cosette has commenced commercial shipments, triggering the 180 days of market...

Termination of Proposed Acquisition of Mayne Pharma

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (Cosette), a U.S.-based, fully integrated pharmaceutical company, confirms that on 9 December 2025 it served a notice on Mayne Pharma Group Limited (Mayne Pharma, ASX: Ticker MYX) terminating the agreement between Cosette and Mayne Pharma under which Cosette was to acquire all the outstanding shares of Mayne Pharma (Scheme Implementation Deed). Cosette also notes the announcements from Mayne Pharma on 10 December 2025 and 11 Dece...

Cosette Pharmaceuticals Appoints Jeff Neubig as Vice President, Quality and Regulatory Affairs

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc., a U.S.-based, fully integrated, pharmaceutical company, announced today that it has appointed Jeff Neubig as Vice President, Quality and Regulatory Affairs. In this critical role, Jeff will lead Cosette’s best-in-class quality and regulatory affairs organizations, maintaining the company’s rigorous quality standards and further establishing Cosette’s strong position as a respected and reliable supplier of high-quality medicines....
Back to Newsroom